Get the Stockscreener App
3.32
7.79%
0.24
After Hours:
3.20
-0.12
-3.61%
Nkarta Inc stock is traded at $3.32, with a volume of 1.32M.
It is up +7.79% in the last 24 hours and up +40.68% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$3.08
Open:
$3.13
24h Volume:
1.32M
Relative Volume:
1.64
Market Cap:
$236.69M
Revenue:
-
Net Income/Loss:
$-104.08M
P/E Ratio:
-2.3598
EPS:
-1.4069
Net Cash Flow:
$-89.91M
1W Performance:
+23.42%
1M Performance:
+40.68%
6M Performance:
+68.53%
1Y Performance:
+78.49%
1-Day Range:
$3.06
$3.35
1-Week Range:
$2.675
$3.35
52-Week Range:
$1.63
$3.65
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
3.32 | 219.58M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Q1'26 Earnings: revenue estimate is 0 USD - TradingView
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat
[ARS] Nkarta, Inc. SEC Filing - Stock Titan
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan
NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Nkarta cell therapy trial may soon offer outpatient treatment option in AAV - ANCA Vasculitis News
Nkarta (NKTX) Stock Dividend Safety (Underperforming) 2026-04-20Crowd Trend Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Nkarta (NKTX) Stock: Why It Could Change (In Focus) 2026-04-18Private Capital - Cổng thông tin điện tử Tỉnh Sơn La
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - The Globe and Mail
Nkarta receives FDA agreement for outpatient NKX019 dosing By Investing.com - Investing.com India
Should I buy Nkarta (NKTX) - Zacks Investment Research
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers - Sahm
NKTX: Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway - TradingView
Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers - marketscreener.com
Nkarta receives FDA agreement for outpatient NKX019 dosing - Investing.com
Nkarta Reports FDA Agreement on Outpatient Dosing of NKX019 - marketscreener.com
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials - Stock Titan
CEO Moves: Will Nkarta Inc stock benefit from M A2026 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Aug PostEarnings: Is Nkarta Inc stock suitable for long term investing2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Nkarta to Participate in Needham Virtual Healthcare Conference - Bitget
Nkarta leaders to discuss autoimmune cell therapy at Needham event - Stock Titan
Ideas Watch: Does Nkarta Inc have declining or rising EPSGap Down & High Win Rate Trade Tips - baoquankhu1.vn
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Layoff Watch: What analysts say about Nkarta Inc stock2026 Technicals & Real-Time Buy Zone Alerts - baoquankhu1.vn
Is Nkarta (NKTX) Stock Good for Beginners | Price at $2.37, Up 2.16%Most Discussed Stocks - Newser
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
[EFFECT] Nkarta, Inc. SEC Filing - Stock Titan
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent - Stock Titan
NKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho - Defense World
NKTX PE Ratio & Valuation, Is NKTX Overvalued - Intellectia AI
Mizuho lowers Nkarta stock price target on sales ramp moderation - Investing.com
Mizuho lowers Nkarta stock price target on sales ramp moderation By Investing.com - Investing.com India
HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX) - MarketBeat
Nkarta files $350M shelf offering, plans $100M ATM stock sale via Stifel - MSN
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating - Moomoo
Risk Hedge: Will Nkarta Inc stock go up in YEARPortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mahmood Nadir | President |
Jan 15 '26 |
Sale |
2.07 |
5,649 |
11,693 |
167,727 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '25 |
Sale |
1.79 |
1,790 |
3,204 |
320,069 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):